San Diego-based Sangart, a biopharmaceuticals firm focused on the commercialization of oxygen therapeutics, said Thursday that it has raised $50M in a Series F funding round. Names of investors were not disclosed, however, the firm said the round came from existing investors. According to Sangart, the funding round brings the company's total raised under its Series F round to approximately $100M. The new funding will go towards further clinical development of its products. Sangart's Series F, which initially closed in April of 2007, was led by Leucadia National Corporation. More information »